Livzon Pharmaceutical Group Inc Total Assets
Livzon Pharmaceutical Group Inc total assets. Based on the latest financial reports, Livzon Pharmaceutical Group Inc (000513) holds total assets worth CN¥24.19 Billion CNY (≈ $3.54 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of Livzon Pharmaceutical Group Inc for how efficiently the company converts equity into cash flow.
Total Assets of Livzon Pharmaceutical Group Inc (1992–2025)
Total assets of Livzon Pharmaceutical Group Inc from 1992 to 2025. This chart illustrates how Livzon Pharmaceutical Group Inc's total assets have evolved over time, based on quarterly financial data. See 000513 live share price for real-time trading data and today's change.
Livzon Pharmaceutical Group Inc - Asset Composition Analysis
Livzon Pharmaceutical Group Inc Total Assets Breakdown (December 2025)
Livzon Pharmaceutical Group Inc total assets breakdown as of December 2025. Livzon Pharmaceutical Group Inc's total assets of CN¥24.19 Billion consist of 67.2% current assets and 32.8% non-current assets. Explore 000513 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 38.8% |
| Accounts Receivable | CN¥3.50 Billion | 14.6% |
| Inventory | CN¥1.56 Billion | 6.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥833.72 Million | 3.5% |
| Goodwill | CN¥124.91 Million | 0.5% |
Asset Composition Trend (1992–2025)
This chart illustrates how Livzon Pharmaceutical Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Livzon Pharmaceutical Group Inc's current assets represent 67.2% of total assets in 2025, a decrease from 74.3% in 1992.
- Cash Position: Cash and equivalents constituted 38.8% of total assets in 2025, up from 13.5% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1992.
- Asset Diversification: The largest asset category is accounts receivable at 14.6% of total assets.
Livzon Pharmaceutical Group Inc Competitors by Total Assets
Key competitors of Livzon Pharmaceutical Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Livzon Pharmaceutical Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 2.28 | 2.20 |
| Quick Ratio | 1.77 | 2.01 | 1.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥7.67 Billion | CN¥9.23 Billion | CN¥7.77 Billion |
Livzon Pharmaceutical Group Inc - Advanced Valuation Insights
This section examines the relationship between Livzon Pharmaceutical Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | CN¥23.99 Billion |
| Market Capitalization | $2.45 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Livzon Pharmaceutical Group Inc's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Livzon Pharmaceutical Group Inc's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Livzon Pharmaceutical Group Inc (1992–2025)
The table below shows the annual total assets of Livzon Pharmaceutical Group Inc from 1992 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥23.99 Billion ≈ $3.51 Billion |
-1.92% |
| 2024-12-31 | CN¥24.46 Billion ≈ $3.58 Billion |
-2.35% |
| 2023-12-31 | CN¥25.04 Billion ≈ $3.66 Billion |
+0.71% |
| 2022-12-31 | CN¥24.87 Billion ≈ $3.64 Billion |
+11.16% |
| 2021-12-31 | CN¥22.37 Billion ≈ $3.27 Billion |
+8.65% |
| 2020-12-31 | CN¥20.59 Billion ≈ $3.01 Billion |
+14.54% |
| 2019-12-31 | CN¥17.98 Billion ≈ $2.63 Billion |
+3.09% |
| 2018-12-31 | CN¥17.44 Billion ≈ $2.55 Billion |
+9.68% |
| 2017-12-31 | CN¥15.90 Billion ≈ $2.33 Billion |
+50.99% |
| 2016-12-31 | CN¥10.53 Billion ≈ $1.54 Billion |
+30.35% |
| 2015-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
+10.61% |
| 2014-12-31 | CN¥7.30 Billion ≈ $1.07 Billion |
+11.22% |
| 2013-12-31 | CN¥6.57 Billion ≈ $960.81 Million |
+16.55% |
| 2012-12-31 | CN¥5.63 Billion ≈ $824.40 Million |
+22.40% |
| 2011-12-31 | CN¥4.60 Billion ≈ $673.55 Million |
+25.69% |
| 2010-12-31 | CN¥3.66 Billion ≈ $535.86 Million |
+17.21% |
| 2009-12-31 | CN¥3.12 Billion ≈ $457.19 Million |
+6.86% |
| 2008-12-31 | CN¥2.92 Billion ≈ $427.85 Million |
-0.74% |
| 2007-12-31 | CN¥2.95 Billion ≈ $431.05 Million |
+17.12% |
| 2006-12-31 | CN¥2.52 Billion ≈ $368.05 Million |
+16.25% |
| 2005-12-31 | CN¥2.16 Billion ≈ $316.61 Million |
-1.74% |
| 2004-12-31 | CN¥2.20 Billion ≈ $322.21 Million |
+3.41% |
| 2003-12-31 | CN¥2.13 Billion ≈ $311.58 Million |
+14.65% |
| 2002-12-31 | CN¥1.86 Billion ≈ $271.77 Million |
+11.08% |
| 2001-12-31 | CN¥1.67 Billion ≈ $244.65 Million |
+7.98% |
| 2000-12-31 | CN¥1.55 Billion ≈ $226.56 Million |
-0.61% |
| 1999-12-31 | CN¥1.56 Billion ≈ $227.96 Million |
+8.21% |
| 1998-12-31 | CN¥1.44 Billion ≈ $210.67 Million |
-4.66% |
| 1997-12-31 | CN¥1.51 Billion ≈ $220.98 Million |
+14.69% |
| 1996-12-31 | CN¥1.32 Billion ≈ $192.68 Million |
+18.64% |
| 1995-12-31 | CN¥1.11 Billion ≈ $162.40 Million |
+27.55% |
| 1994-12-31 | CN¥870.12 Million ≈ $127.33 Million |
+9.14% |
| 1993-12-31 | CN¥797.27 Million ≈ $116.67 Million |
+34.16% |
| 1992-12-31 | CN¥594.26 Million ≈ $86.96 Million |
-- |
About Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more